AU2002226086C1 - Silensed anti-CD28 antibodies and use thereof - Google Patents

Silensed anti-CD28 antibodies and use thereof Download PDF

Info

Publication number
AU2002226086C1
AU2002226086C1 AU2002226086A AU2002226086A AU2002226086C1 AU 2002226086 C1 AU2002226086 C1 AU 2002226086C1 AU 2002226086 A AU2002226086 A AU 2002226086A AU 2002226086 A AU2002226086 A AU 2002226086A AU 2002226086 C1 AU2002226086 C1 AU 2002226086C1
Authority
AU
Australia
Prior art keywords
antibody
seq
cells
expression
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002226086A
Other languages
English (en)
Other versions
AU2002226086A1 (en
AU2002226086B2 (en
Inventor
Yasuyuki Higashi
Paul Hinton
Nobuo Seki
Kouichi Tamura
J. Yun Tso
Hirotsugu Ueda
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AU2002226086A1 publication Critical patent/AU2002226086A1/en
Application granted granted Critical
Publication of AU2002226086B2 publication Critical patent/AU2002226086B2/en
Assigned to ASTELLAS PHARMA, INC. reassignment ASTELLAS PHARMA, INC. Request for Assignment Assignors: FUJISAWA PHARMACEUTICAL CO., LTD.
Publication of AU2002226086C1 publication Critical patent/AU2002226086C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002226086A 2000-12-14 2001-12-14 Silensed anti-CD28 antibodies and use thereof Ceased AU2002226086C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US60/255,155 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (3)

Publication Number Publication Date
AU2002226086A1 AU2002226086A1 (en) 2002-08-29
AU2002226086B2 AU2002226086B2 (en) 2005-08-25
AU2002226086C1 true AU2002226086C1 (en) 2006-03-09

Family

ID=22967074

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002226086A Ceased AU2002226086C1 (en) 2000-12-14 2001-12-14 Silensed anti-CD28 antibodies and use thereof
AU2608602A Pending AU2608602A (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2608602A Pending AU2608602A (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (ko)
JP (1) JP2004515243A (ko)
KR (1) KR20040020866A (ko)
CN (1) CN1272345C (ko)
AR (1) AR031924A1 (ko)
AU (2) AU2002226086C1 (ko)
BR (1) BR0116686A (ko)
CA (1) CA2432736A1 (ko)
CZ (1) CZ20031909A3 (ko)
HU (1) HUP0400697A3 (ko)
IL (1) IL156262A0 (ko)
MX (1) MXPA03005327A (ko)
NO (1) NO20032542L (ko)
NZ (1) NZ526569A (ko)
PL (1) PL363239A1 (ko)
RU (1) RU2261723C2 (ko)
WO (1) WO2002047721A1 (ko)
ZA (1) ZA200305384B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113692286A (zh) * 2019-03-14 2021-11-23 比昂生物制剂公司 一种用于免疫抑制的方法
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein

Also Published As

Publication number Publication date
EP1341553A4 (en) 2004-07-28
JP2004515243A (ja) 2004-05-27
BR0116686A (pt) 2003-12-30
RU2261723C2 (ru) 2005-10-10
AU2002226086B2 (en) 2005-08-25
AR031924A1 (es) 2003-10-08
RU2003121231A (ru) 2005-02-10
CZ20031909A3 (cs) 2003-11-12
NZ526569A (en) 2005-07-29
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
PL363239A1 (en) 2004-11-15
CA2432736A1 (en) 2002-06-20
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
ZA200305384B (en) 2004-10-11
MXPA03005327A (es) 2004-12-03
IL156262A0 (en) 2004-01-04
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
AU2608602A (en) 2002-06-24
NO20032542D0 (no) 2003-06-05
EP1341553A1 (en) 2003-09-10
CN1272345C (zh) 2006-08-30

Similar Documents

Publication Publication Date Title
RU2244720C2 (ru) Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента
EP0966485B1 (en) MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME
CA2212750C (en) Humanized antibodies against cd3
KR100191152B1 (ko) Cd4 특이적 재조합 항체
AU751064B2 (en) Antibodies against human CD40
AU2002226086C1 (en) Silensed anti-CD28 antibodies and use thereof
US20040052783A1 (en) Humanized antibodies against CD3
PL180157B1 (en) Humanised antibodies and their application
US5951983A (en) Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
AU754185B2 (en) LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
CA2544365A1 (en) Modified anti-cd52 antibody
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 OCT 2005.

FGA Letters patent sealed or granted (standard patent)
TC Change of applicant's name (sec. 104)

Owner name: ASTELLAS PHARMA, INC.

Free format text: FORMER NAME: FUJISAWA PHARMACEUTICAL CO., LTD.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 OCT 2005

MK14 Patent ceased section 143(a) (annual fees not paid) or expired